Technologies

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Inert biomedical devices with modular load-bearing function designed with peculiar multi-domain composite microstructures. The reference compositional system is Zirconia-Alumina with a prevailing overall composition of customizable zirconia or alumina. Examples of devices are 3D structures consisting of parts with differentiated functional properties, due to different composition/microstructure/architecture, and further functionalizable ex-post to favor and improve the stabilization of the implantation by newly formed bone in superior quantity and quality.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.